Skip to main content
ReproCELL Incorporated logo

ReproCELL Incorporated — Investor Relations & Filings

Ticker · 4978 ISIN · JP3974770004 LEI · 529900NM7KR32GGRSU46 T Professional, scientific and technical activities
Filings indexed 61 across all filing types
Latest filing 2025-11-13 Regulatory Filings
Country JP Japan
Listing T 4978

About ReproCELL Incorporated

https://www.reprocell.com/

ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly cites '金融商品取引法第24条の5の2第1項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 24
2025-11-13 Japanese
半期報告書-第24期(2025/04/01-2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by ReproCELL Incorporated under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management analysis (MDA), and business performance data for the interim period (April 1, 2025, to September 30, 2025). This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2025
2025-11-13 Japanese
内部統制報告書-第23期(2024/04/01-2025/03/31)
Audit Report / Information Classification · 95% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly cites the legal basis as "金融商品取引法第24条の4の4第1項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1). This structure and content—detailing the framework, scope, criteria, and conclusion regarding the effectiveness of internal controls over financial reporting as of a specific fiscal year-end (March 31, 2025)—is characteristic of the internal control report required under Japanese securities law, which is analogous to the Sarbanes-Oxley Section 404 report in the US context. While there isn't a direct 1:1 mapping in the provided codes, the closest fit for a comprehensive, standalone report detailing internal control effectiveness, which is often filed alongside the annual report but is distinct, is the Audit Report/Information (AR) category, as it deals with assurance and control testing results. However, given the specific nature of this document being solely the Internal Control Report (which is a mandatory component of the annual filing process in Japan, similar to the US 10-K), and lacking a specific 'Internal Control Report' code, 'AR' (Audit Report / Information) is the most appropriate classification among the choices for a formal, assurance-related document that is not the full Annual Report (10-K) or a simple Earnings Release (ER). The document is substantial and detailed, ruling out RPA or RNS based on the 'MENU VS MEAL' rule. FY 2025
2025-06-26 Japanese
確認書
Audit Report / Information Classification · 98% confidence The document text contains Japanese regulatory headers, specifically mentioning "有価証券報告書" (Yuka Shoken Hokokusho), which translates to 'Securities Report' or 'Annual Securities Report'. It also references the Financial Instruments and Exchange Act ("金融商品取引法") and lists the submission date, company name, and responsible officers confirming the appropriateness of the report's contents for the fiscal year ending March 31, 2025. In the context of US SEC filings, the closest equivalent to a comprehensive annual securities report is the 10-K. Given the context of a comprehensive annual filing confirming its accuracy, the classification should align with the Annual Report category (10-K), even though the specific Japanese document type is slightly different from the US 10-K form. The document is the report itself, not an announcement of the report's release, and it is comprehensive, not just highlights (ruling out ER). FY 2025
2025-06-26 Japanese
有価証券報告書-第23期(2024/04/01-2025/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the standard annual financial report filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains comprehensive financial data, business indicators, and management information for the fiscal year ending March 31, 2025. This corresponds to the 10-K filing category in the provided schema. FY 2025
2025-06-26 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text explicitly contains the title "第2四半期報告書" (Second Quarter Report) and references the period "第23期中(自 2024年4月1日 至 2024年9月30日)" (The 23rd period, from April 1, 2024, to September 30, 2024). It is a formal filing submitted to the Kanto Local Finance Bureau ("関東財務局長") under the Financial Instruments and Exchange Act ("金融商品取引法"). This structure and content strongly indicate a comprehensive financial report for an interim period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). Although it is a confirmation statement regarding the report's appropriateness, the core subject matter is the semi-annual report itself, making IR the most appropriate classification over a general regulatory filing (RNS) or a report publication announcement (RPA), given its substantive nature regarding the reporting period.
2024-11-13 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.